Intervention Protocol

You have free access to this content

Lurasidone versus placebo for schizophrenia

  1. Lorna Donnelly1,*,
  2. Stephanie Sampson2

Editorial Group: Cochrane Schizophrenia Group

Published Online: 28 MAR 2013

DOI: 10.1002/14651858.CD010448

How to Cite

Donnelly L, Sampson S. Lurasidone versus placebo for schizophrenia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD010448. DOI: 10.1002/14651858.CD010448.

Author Information

  1. 1

    Norfolk and Suffolk Foundation Trust, Acute Psychiatric Services, Bury St Edmunds, Suffolk, UK

  2. 2

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

*Lorna Donnelly, Acute Psychiatric Services, Norfolk and Suffolk Foundation Trust, Wedgewood House, West Suffolk Hospital, Hardwick Lane, Bury St Edmunds, Suffolk, IP332QZ, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 28 MAR 2013



Additional references

Altman 1996
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
Broome 2005
Citrome 2011
  • Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practise February 2011;65(2):189–210.
Davis 2003
  • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry June 2003;60(6):553-64.
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
Donner 2002
Egger 1997
Elbourne 2002
  • Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
Gottesman 1991
  • Gottesman, Irving I. Schizophrenia Genesis: The Origins of Madness. A series of Books in Psychology. Vol. xiii, New York, NY, US: WH Freeman/Times Books/ Henry Holt & Co, 1991.
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from
Hussar 2011
Hutton 2009
Jablensky 2000
  • Gelder MG, Lopez-Ibor JJ, Andreasen N. Course and outcome of schizophrenia and their prediction. Oxford Textbook of Psychiatry. Vol. 1, Oxford University Press, 2000:612-21.
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Leucht 2005
Leucht 2005a
  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
Leucht 2007
  • Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Nadeem 2004
  • Nadeem Z, McIntosh A, Lawrie S. EBMH notebook: schizophrenia. Evidence-Based Mental Health 2004;7:2-3.
NICE 2009
  • National Institute for Health and Clinical Excellence. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. In: Updated editor(s). National Clinical Guideline Number 82. London: National Institute for Health and Clinical Excellence, 2009.
Nolan 2012
  • Nolan SF, Roman MW. Lurasidone: an atypical antipsychotic. Issues in Mental Health Nursing 2012;33:342–3.
Overall 1962
Samalin 2011
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.